No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 10 of the 34 quarters in the window, leaving 24 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 5.2x · 10Y median 30.9x · 1st percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 35
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T16:27:30.679Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T16:27:30.679Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T16:27:30.679Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T16:27:30.679Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T16:27:30.679Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T16:27:30.679Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T16:27:30.679Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T16:27:30.679Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Liquidia Corporation (LQDA) stock was $26.27 as of Oct 6, 2026, 12:25 PM EDT, down 4.95% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +23.1% · 3-year avg +58.6%/yr · 5-year avg +59.0%/yr
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension.
Medical - Pharmaceuticals · Morrisville, NC
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 2, 2026
27 days away
EPS Estimate
0.90
Revenue Est.
$202.11M
Last Quarter Results
EPS
$0.74
vs Estimate
$0.84
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1LQDA | $2.34B | $26.27 | -4.95% | +23.11% | +59.01% | N/A | N/A |
| 2NRIX | $2.36B | $22.79 | -0.41% | +142.89% | -5.51% | N/A | vs LQDA |
| 3HRMY | $2.30B | $39.67 | -0.63% | +46.07% | +0.91% | N/A | vs LQDA |
| 4ADMA | $2.38B | $10.26 | +1.52% | -30.91% | +54.74% | +3.85% | vs LQDA |
| 5ALMR | $2.38B | $34.39 | -9.80% | N/A | N/A | N/A | vs LQDA |
| 6MRVI | $2.28B | $8.26 | -3.05% | +174.40% | -27.63% | N/A | vs LQDA |
11.97
$171.68M
vs Estimate
$168.48M
Consensus Rating
Based on 6 analysts
Average Price Target
$49.67
+89.1% upside
Low
$30.00
Current
$26.27
High
$72.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.72 | $0.83 | $0.93 | 3 |
| Quarter ending Dec 2026 | $-0.56 | $0.43 | $1.40 | 3 |
| Quarter ending Mar 2027 | $0.01 | $0.09 | $0.15 | 1 |
| Quarter ending Jun 2027 | $0.03 | $0.19 | $0.33 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $1.77 | $2.49 | $3.65 | 5 |
| FY 2027 | $0.89 | $2.34 | $3.96 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $194.71M | $202.11M | $209.50M | 4 |
| Quarter ending Dec 2026 | $59.91M | $163.34M | $266.78M | 4 |
| Quarter ending Mar 2027 | $41.54M | $119.08M | $183.07M | 2 |
| Quarter ending Jun 2027 | $47.02M | $134.78M | $207.21M | 2 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $566.12M | $669.96M | $773.79M | 5 |
| FY 2027 | $398.49M | $739.00M | $1.08B | 5 |
